A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

IRB/UVA Tracking #
19675
Contact
Gianna R Strand
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Karen Ballen
Status
OPEN TO ACCRUAL
Ages
Adult